Bio-Path Holdings, Inc. (BPTH) Stock Price & Analysis
Bio-Path Holdings, Inc. (BPTH) rose 12.50% to USD 0.04 as of June 10, 2026 at 03:40 UTC, according to Nexqual real-time market data.
BPTH last closed at USD 0.03; the session ranged USD 0.03–0.05 on volume of 31,738 shares. Market capitalization is $1.81M, with a 52-week range of USD 0.01–0.23 (PNK). Source: Nexqual, June 10, 2026 at 03:40 UTC.
Key Statistics (as of June 10, 2026 at 03:40 UTC)
| Price | USD 0.04 |
|---|---|
| Change | ▲ 12.50% (up) |
| Previous Close | USD 0.03 |
| Open | USD 0.03 |
| Day Range | USD 0.03 – 0.05 |
| 52-Week Range | USD 0.01 – 0.23 |
| Volume | 31,738 shares |
| Market Cap | $1.81M |
| Exchange | PNK |
Technical Analysis (BPTH)
Nexqual's technical model rates BPTH "SELL" based on 1 bullish and 4 bearish signals across 124 daily candles, as of June 10, 2026 at 03:40 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 46.44 (neutral) |
| vs SMA50 | Below (USD 0.05) |
| MACD | -0 (negative) |
Analyst Ratings (BPTH)
Wall Street analysts rate BPTH "None", per Nexqual as of June 10, 2026 at 03:40 UTC.
| Consensus Rating | None |
|---|
Earnings (BPTH)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-06-30 | USD -0.55 vs est -0.4 ▼ miss |
| 2025-03-31 | USD -0.4 vs est -0.38 ▼ miss |
| 2024-12-31 | USD -0.07 vs est -0.37 ▲ beat |
| 2024-09-30 | USD -0.7 vs est -1.02 ▲ beat |
Source: Nexqual, June 10, 2026 at 03:40 UTC.
Financials & Fundamentals (BPTH)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Current Ratio | 0.07 |
| Total Cash | $12,000 |
| Total Debt | $511,000 |
| Free Cash Flow | $2.29M |
Source: Nexqual, June 10, 2026 at 03:40 UTC.
Financial Health Score (BPTH)
Nexqual rates Bio-Path Holdings, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 03:40 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $12K cash, no debt |
| Cash Flow | Weak — Operating cash flow -$321K |
| Efficiency | Mixed — No data |
Ownership (BPTH)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +0.87% |
| Shares Outstanding | 50.30M |
| Float | 49.91M |
| Short % of Float | +1.38% |
Source: Nexqual, June 10, 2026 at 03:40 UTC.
Leadership (BPTH)
Bio-Path Holdings, Inc. is led by Vikram Paul Grover C.F.A. (age 55), President, CEO, CFO & Director, per Nexqual as of June 10, 2026 at 03:40 UTC.
| President, CEO, CFO & Director | Vikram Paul Grover C.F.A. (age 55) |
|---|---|
| Co-Founder, Director of Investor Relations & Secretary | Douglas P. Morris (age 69) |
| Senior Vice President of Finance, Accounting & Administration | Anthony Price |
| Senior Vice President of Research, Development & Clinical Design | Ana Tari Ashizawa |
Major Backers & Investors (BPTH)
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 0.16% |
Source: Nexqual, June 10, 2026 at 03:40 UTC.
From Bio-Path Holdings, Inc.'s Latest SEC 10-K Filing (filed 2025-03-27)
Key Strengths & Strategy (as disclosed to the SEC)
- Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States.
- Its drug delivery and antisense technology is the DNAbilize, a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body's enzymes when circulating in vivo, incorporated inside of a lipid bilayer having neutral charge.
- The company's lead drug candidate is the Prexigebersen (BP1001), which is in phase 2 clinical trial for the treatment of untreated acute myeloid leukemia (AML).
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| TENX | Tenax Therapeutics, Inc. | USD 10.73 | ▲ 0% |
| AKTX | Akari Therapeutics Plc | USD 15 | ▼ 0.46% |
| ADIL | Adial Pharmaceuticals, Inc | USD 2.13 | ▼ 3.62% |
| RKDA | Arcadia Biosciences, Inc. | USD 0.92 | ▼ 14.02% |
| VTVT | vTv Therapeutics Inc. | USD 31.77 | ▼ 1.15% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:40 UTC. This page is informational and not investment advice.